A comparative crossover study on the treatment of heartburn and epigastric pain: Liquid Gaviscon and a magnesium--aluminium antacid gel.
Forty-four patients with symptoms of gastro-oesophageal reflux were randomly assigned in a crossover trial to treatment for 15-day periods with Liquid Gaviscon (a reflux suppressant) or an antacid gel containing magnesium and aluminium hydroxide. Good relief of symptoms was reported by 84% of patients during therapy with Liquid Gaviscon compared to only 23% during antacid therapy. Relief of symptoms was obtained within 15 minutes by 68% of patients during therapy with Liquid Gaviscon compared to only 9% during antacid treatment. The beneficial effect lasted for more than 4 hours in 75% of patients during treatment with Liquid Gaviscom compared to only 23% of patients obtaining long-term relief during antacid therapy.
D000005:Abdomen; D000328:Adult; D000368:Aged; D000464:Alginates / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D000863:Antacids / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006356:Heartburn / Q000188:drug therapy*; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008276:Magnesium Hydroxide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D012824:Silicic Acid / Q000627:therapeutic use*; D012822:Silicon Dioxide / Q000627:therapeutic use*; D017693:Sodium Bicarbonate
D000464:Alginates; D000863:Antacids; D001639:Bicarbonates; D004338:Drug Combinations; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D012822:Silicon Dioxide; D017693:Sodium Bicarbonate; D008274:Magnesium; D008276:Magnesium Hydroxide